Aptevo Therapeutics Inc. Files Amendment No. 2 to S-1 Registration Statement

TL;DR

<b>Aptevo Therapeutics Inc. has filed an amendment to its S-1 registration statement, indicating progress towards a public offering.</b>

AI Summary

Aptevo Therapeutics Inc. (APVO) filed a Amended IPO Registration (S-1/A) with the SEC on April 9, 2024. Aptevo Therapeutics Inc. filed Amendment No. 2 to its Form S-1 Registration Statement on April 9, 2024. The filing is in relation to the Securities Act of 1933, with registration number 333-278103. The company's principal executive offices are located at 2401 4th Ave., Suite 1050, Seattle, Washington. Marvin L. White is listed as President and Chief Executive Officer. The filing indicates the proposed sale of securities will commence as soon as practicable after the effective date.

Why It Matters

For investors and stakeholders tracking Aptevo Therapeutics Inc., this filing contains several important signals. This amendment suggests the company is moving forward with its plans to raise capital through a public offering, which could provide funding for its operations and development pipeline. The S-1 filing is a crucial step for companies seeking to go public, providing detailed information to potential investors about the business, its financials, and risks.

Risk Assessment

Risk Level: low — Aptevo Therapeutics Inc. shows low risk based on this filing. The filing is an amendment to a registration statement, not a new offering announcement, thus carrying minimal immediate market risk.

Analyst Insight

Monitor for further amendments or the effectiveness of the registration statement to understand the details and timing of the potential public offering.

Key Numbers

• 333-278103 — Registration Number (S-1 Registration Statement)
• 2024-04-09 — Filing Date (Amendment No. 2)
• 2834 — SIC Code (Pharmaceutical Preparations)
• 811567056 — IRS Number (Aptevo Therapeutics Inc.)

Key Players & Entities

• Aptevo Therapeutics Inc. (company) — Registrant
• Marvin L. White (person) — President and Chief Executive Officer
• Sean M. Donahue (person) — Copies to
• Paul Hastings LLP (company) — Legal counsel
• SoYoung Kwon (person) — Senior Vice President and General Counsel
• Charles E. Phillips (person) — Copies to
• Ellenoff Grossman & Schole LLP (company) — Legal counsel

FAQ

Industry Context

Aptevo Therapeutics Inc. operates in the pharmaceutical preparations industry, focusing on the development of novel therapeutics.

Regulatory Implications

The filing is made under the Securities Act of 1933, which governs the registration of securities offered to the public.

What Investors Should Do

1. Review the full S-1 filing for detailed financial information and risk factors.
2. Track subsequent filings for updates on the offering's progress and terms.
3. Analyze the company's business strategy and pipeline as outlined in the registration statement.

Key Dates

• 2024-04-09: Filing of Amendment No. 2 to Form S-1 — Indicates progress in the registration process for a public offering.

Year-Over-Year Comparison

This is an amendment to a previously filed S-1 registration statement, indicating ongoing regulatory processes rather than a new filing event.

Key Financial Figures

• $0.001 — #x201d;) of our common stock, par value $0.001 per share (common stock) together with
• $5.42 — sumed combined public offering price of $5.42 per share and common warrant (the last
• $0.0001 — of common stock at an exercise price of $0.0001 per share. Each pre-funded warrant is b
• $100,000 — cement agent fee, will be approximately $100,000. The delivery of the shares of common

Filing Documents

• apvo-2024-s1a_-_amend_2.htm (S-1/A) — 850KB
• img179049612_0.jpg (GRAPHIC) — 7KB
• img179049612_1.jpg (GRAPHIC) — 58KB
• img179049612_2.jpg (GRAPHIC) — 516KB
• img179049612_3.jpg (GRAPHIC) — 4KB
• 0000950170-24-043059.txt (&nbsp;) — 1657KB

USE OF PROCEEDS

USE OF PROCEEDS 10 CAPITALIZATION 11

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 14

description of securities we are offering

description of securities we are offering 19 PLAN OF DISTRIBUTION 23 I ncorporation of certain information by reference 26 WHERE YOU CAN FIND MORE INFORMATION 26 LEGAL MATTERS 27 EXPERTS 27 ABOUT THIS PROSPECTUS We incorporate by reference important information into this prospectus. You may obtain the information incorporated by reference without charge by following the instructions under &#x201c; Where You Can Find More Information.&#x201d; You should carefully read this prospectus as well as additional information described under &#x201c; Incorporation of Certain Information by Reference ,&#x201d; before deciding to invest in our securities. We have not, and the placement agent has not, authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby, and only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date. The information incorporated by reference or provided in this prospectus contains statistical data and estimates, including those relating to market size and competitive position of the markets in which we participate, that we obtained from our own internal estimates and research, as well as from industry and general publications and research, surveys and studies conducted by third parties. Industry publications, studies and surveys generally state that they have bee

View Full Filing

View this S-1/A filing on SEC EDGAR